


# Child with growth disorders



Beata Pyrżak  
Klinika Pediatrii i Endokrynologii  
Warszawski Uniwersytet Medyczny

# In the diagnostic approach – two important questions

---

- (1) Which criteria should be used to refer children with impaired growth and to start diagnostic procedures?
- (2) What kind of diagnostic approach should be followed in the referred group of children?



# Referral Criteria for Children with Short Stature

---

1. Height can be compared with age references, and expressed as standard deviation score (SDS) or centile position. Height SDS (HSDS) is a measure of the deviation of the individual height from the mean, and is expressed as the number of standard deviations below or above the mean height of the population for the same age and sex.
2. HSDS can be compared with the sex-corrected midparental height (target height) SDS. E.g. formula  $(\text{father's height} + \text{mother's height} + 13 \text{ cm})/2$  for boys and  $(\text{father's height} + \text{mother's height} - 13 \text{ cm})/2$  for girls

# Growth

---

The criteria most commonly used in clinical practice in short stature are:

- (1) Height below  $-2$  SDS for age, sex and ethnic group.
- (2) Normal height, i.e. between  $\pm 2$  SDS for the general population, but  $>2$  SDS below the growth curve corresponding to the patient's TH (midparental target height)
- (3) Projected adult height (prediction of adult height)  $>2$  SDS below the TH.
- (4) Persistent low GV.

Short stature can be defined as height more than 2 SD below the mean

Tall stature as height more than 2 SD above the mean.



# Growth

---

- 3% of children will be or more than -2 SD below the mean (short stature)
- 3% of children will be or more than +2 SD above the mean (tall stature)

# Growth hormone physiology

---

Two hypothalamic hormones regulate GH secretion:

**Growth Hormone Releasing Hormone (GHRH)** with a stimulatory action, and **somatostatin (SST)** with an inhibitory effect .

- Various synthetically produced GH releasing compounds and the recently discovered natural hormone **ghrelin** probably have a dual effect in increasing the release of GHRH and inhibiting SST action.
- Stress, hypoglycaemia and ingestion of protein -high levels of circulating amino acids stimulates GH secretion, while high levels of glucose and FFA inhibits secretion.








Fig. 23-16

# Factors that stimulate and suppress GH secretion under physiological conditions







**Figure 1** Schematic diagram of the GH-IGF axis, showing identified and theoretical defects: (a) defects of the extracellular domain of the GHR, affecting binding of GH; (b) defects in GHR dimerization; (c) defects of the transmembrane domain of the GHR; (d) defects of the intracellular domain of the GHR; (e) defects of JAK2 (theoretical at this time); (f) defects of STAT5b; (g) defects of STAT5a (theoretical at this time); (h) defects of transcriptional regulation of IGF-I (theoretical at this time); (i) defects of the IGF-I gene; (j) defects of IGFBPs, affecting IGF availability (theoretical at this time); (k) defects of the IGF receptor; (l) defects of IGF receptor signal transduction (theoretical at this time); (m) defects at the epiphyseal growth plate, potentially affecting IGF action. GH, growth hormone; GHR, growth hormone receptor; JAK2, janus-family tyrosine kinase 2; PI3K, phosphatidylinositol-3 kinase; ERK, extracellular signal-regulated kinase; STAT, signal transducer and activator of transcription; ISRE, interferon-stimulated response element; GAS, interferon-gamma-activated sequences; IGF, insulin-like growth factor; IGFBP, IGF binding proteins; IGF-IR, IGF-I receptor; IRS, insulin receptor substrate.

## **Effects on Growth**

Growth is a very complex process, and requires the coordinated action of several hormones.

### **The major role of growth hormone**

- in stimulating body growth is to stimulate the liver and other tissues to secrete IGF-I.
- stimulates proliferation of chondrocytes (cartilage cells), resulting in bone growth.
- Growth hormone have a direct effect on bone growth in stimulating differentiation of chondrocytes.
- IGF-I also appears to be the key player in muscle growth. It stimulates both the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues.



## **Other functions**

Although height growth is the best known effect of GH, it serves many other metabolic functions as well.

- It increases calcium retention, and strengthens and increases the mineralization of bone.
- It increases muscle mass through the creation of new muscle cells (which differs from hypertrophy)
- It promotes lipolysis, which results in the reduction of adipose tissue (body fat).
- It increases protein synthesis and stimulates the growth of all internal organs excluding the brain.
- It plays a role in fuel homeostasis.
- It reduces liver uptake of glucose, an effect that opposes that of insulin.
- It promotes liver gluconeogenesis.
- It contributes to the maintenance and function of pancreatic islets.
- It stimulates the immune system.

## **Growth phases**

Human growth is a rather regular process characterized by a pattern of changing growth rate or height velocity from infancy to adulthood.

In the short-term the height velocity of a healthy individual fluctuates i.e. seasonal or longer periodicity has been shown.

It appears that some phases of growth are more important in their effect on final height. For example a child who is born short has a greater chance of being a short adult. The timing and duration of puberty are also crucial factors in determining final height.




# Growth velocity


- Height and weight at each age are the results of the genetic potential and the health history of the individual.
- **Growth velocity** / Height velocity – linear growth; observation of a child's height over a period of time -at least 6 months of observation/

## Normal Growth velocities at different ages

Age	Average Growth Velocity / Year.
1 <sup>st</sup> year	25cm
2 <sup>nd</sup> year	12-13cm
3 <sup>rd</sup> & 4 <sup>th</sup> year	6-7 cm
5 years- till onset of puberty	5cm/year








← Father 187 cm  
← Mother 166 cm

9 y.o girl with growth  
hormone deficiency  
bone age delay at 6.y.o



← Father 182 cm

← Mother 160 cm


**8 y.o boy with tall  
stature 151 cm / 2 SD  
above the mean/**



## THE GROWTH PLATE

The most important target organ for linear growth is the epiphyseal growth plate, a layer of cartilage found in growing long bones between the epiphysis and the metaphysis. Longitudinal bone growth occurs at the growth plate by endochondral ossification, in which cartilage is formed and then remodeled into bone tissue

.



**Fig. 1.** Histology of the growth plate. The growth plate is a thin cartilage structure situated in the ends of tubular bones. It is commonly subdivided into three distinct zones; the resting, proliferative, and hypertrophic zones.



# Bone age


---

Bone age is used as clinical tool to assess the point at which a child has arrived in his or her skeletal development

- **X- rays of the foot and knee for neonates**
- **X- rays of the wrist and hand for older children**

*(the x-ray is estimate by the methods of Greulich and Pyle, and Tanner and Whitehouse.*

*Greulich and Pyle have definied stages of development of individuals bones in the hand and wrist and the median ages of their occurrence. Next they have selected representative x-rays by sex and age. Since there are always some individual bones that deviate from the median, each standard x-ray is accompanied by a table indicating the „age” of individual bones )*







# Causes of short stature according to the ESPE classification -1-

---

## **A Primary growth disorders**

### *A1 Clinically defined syndromes*

- Turner syndrome
- Cornelia de Lange syndrome
- DiGeorge syndrome (velocardiofacial syndrome)
- Down syndrome
- Noonan syndrome
- Prader-Willi-Labhart syndrome
- Von Recklinghausen's disease (neurofibromatosis type 1)
- Silver-Russell syndrome



# Causes of short stature according to the ESPE classification -2-

---

*A2 Small for gestational age with failure of catch-up growth*

- IGF-I deficiency, IGF resistance
- Due to known cause, e.g. prenatal infections, drugs, smoking, alcohol
- Idiopathic

# Causes of short stature according to the ESPE classification -3-

---

## *A3 Skeletal dysplasias*

- Achondroplasia
- Hypochondroplasia
- Dyschondrosteosis (Leri-Weill and other defects in the SHOX gene)
- Osteogenesis imperfecta I–VI
- Mucopolysaccharidosis (type IH, IS, II–VII)
- Mucopolidosis (type II and III)

## *A4 Dysplasias with defective mineralization*



# Causes of short stature according to the ESPE classification -4-

---

## **B Secondary growth disorders**

*B1 Insufficient nutrient intake (malnutrition)*

*B2 Disorders in organ systems*

- Cardiac disorders
- Pulmonary disorders, e.g. cystic fibrosis
- Liver disorders
- Intestinal disorders, e.g. Crohn's disease, malabsorption syndromes
- Short bowel syndrome
- Renal disorders, e.g. Fanconi syndrome, renal acidosis
- Chronic anemia

# Causes of short stature according to the ESPE classification -5-

---

## *B3 Growth hormone deficiency (secondary IGF-I deficiency)*

- Idiopathic
- Genetic (HESX1, PROP1, POU1F1, LHX3, LHX4, GHRHR, GH)
- Associated with syndromes or cerebral or facial malformations, e.g. septo-optic dysplasia, empty sella syndrome
- Associated with prenatal infections, e.g. rubella
- Acquired (craniopharyngioma, other pituitary tumors, e.g. germinoma, hamartoma)
- Head trauma
- Central nervous system infections
- Granulomatous diseases, e.g. histiocytosis



# Causes of short stature according to the ESPE classification -6-

---

*B4 Other disorders of the growth hormone-IGF axis (primary IGF-I deficiency and resistance)*

- Bioinactive growth hormone
- Abnormalities of the growth hormone receptor (growth hormone insensitivity syndrome, Laron syndrome)
- Abnormalities of GH signal transduction, e.g. STAT5B defect
- ALS (acid-labile subunit) deficiency
- IGF-I deficiency
- IGF resistance (IGF1R defects, postreceptor defects)

# Causes of short stature according to the ESPE classification -7-

---

## *B5 Other endocrine disorders*

- Cushing syndrome
- Hypothyroidism
- Leprechaunism
- Diabetes mellitus (poorly controlled)
- Short adult stature caused by accelerated bone maturation, e.g. precocious puberty, hyperthyroidism, congenital adrenal hyperplasia, exogenous estrogens or androgens



# Causes of short stature according to the ESPE classification -8-

---

## *B6 Metabolic disorders*

- Disorders of calcium and phosphorus metabolism
- Disorders of carbohydrate metabolism
- Disorders of lipid metabolism
- Disorders of protein metabolism

# Causes of short stature according to the ESPE classification -9-

---

## *B7 Psychosocial*

- Emotional deprivation
- Anorexia nervosa
- Depression

## *B8 Iatrogenic*

- Systemic glucocorticoid therapy
- Local glucocorticoid therapy (inhalation, intestinal, other)
- Other medication
- Treatment of childhood malignancy, total body irradiation, chemotherapy, Other specified iatrogenic causes



# Causes of short stature according to the ESPE classification -10-

---

## **C Idiopathic short stature**

- *C1 Familial (idiopathic) short stature*
- *C2 Non-familial (idiopathic) short stature*

# Dysmorphic features in short stature and associated syndrome

Dysmorphic feature	Associated syndrome
Short nose with anteverted nostrils	Smith-Lemli-Opitz
Continuous eyebrows	Cornelia de Lange
Absence of adipose tissue	Leprechaunism
Alopecia	Progeria
Ambiguous genitalia/ abnormal genitalia	Mixed gonadal dysgenesis/ 46,XY/45X chromosomal mosaicism/Smith-Lemli-Opitz/ Aarskog
Asymmetry of the face/ arms/legs	Russell-Silver
Bicuspid aortic valve	Turner
Bird-headed face	Seckel
Broad thumbs and toes	Rubinstein-Taybi



Smith-Lemli-Opitz

autosomal recessive caused by a deficiency of the enzyme 3 beta-hydroxysterol-delta 7-reductase (7-dehydrocholesterol-delta 7-reductase, the final enzyme in the sterol synthetic pathway that converts 7-dehydrocholesterol (7DHC) to cholesterol.



Cleft lip and/or palate  
Clinodactyly  
Coarctatio aortae  
Cryptorchism

Cubiti valgi  
Digital V missing/no nails  
Disproportion  
Elfin face  
Epicanthus  
High arched palate

Hirsutism  
Hypogonadism  
Hypoplastic nipples  
Hypospadia

Inverted nipples  
Lymphedema (congenital)  
Madelung deformity  
Micropenis

Muscular hypotonia

Growth hormone deficiency  
Russell-Silver  
Turner

Noonan, Prader-Willi,  
Rubinstein-Taybi

Turner  
Coffin-Siris  
Skeletal dysplasias  
Williams

Down  
22q11 deletion syndrome,  
SHOX

Coffin-Siris, Cornelia de Lange  
Robinow, Smith-Lemli-Opitz

Turner  
46,XY/45X chromosomal  
mosaicism

Turner

Turner

Leri-Weill, SHOX abnormalitie  
Prader-Willi, growth hormone  
deficiency

Down, Prader-Willi

Nail convexity/dysplasia  
Nevi (multiple)  
Ptosis

Turner  
Turner  
Aarskog, Dubowitz, Noonan,  
Turner

Pulmonary valvular stenosis  
Shawl scrotum  
Short 4th and 5th meta-  
carpals  
Single central incisor  
Small hands/feet  
Telangiectasia in face  
Triangular face  
Webbed neck

Noonan  
Aarskog  
Pseudohypoparathyroidism  
  
Growth hormone deficiency  
Prader-Willi  
Bloom  
Russell-Silver  
Noonan, Turner



# 1. Silver Russell syndrome

S



## **Chromosomes 7 and 11**

- Growth retardation before and after birth
- Large head compared to rest of the body
- Prominent head, narrow chin
- 5th finger clinodactyly
- hemihypoplasia

## Silver-Russell Syndrome

Silver-Russell syndrome (SRS) is a clinically and genetically heterogeneous disorder, characterized by severe pre/postnatal growth retardation, characteristic facies, skeletal asymmetry, and other congenital anomalies. The incidence is estimated as 1:50,000–1:100,000 live births.

### GENETIC/BASIC DEFECTS

1. Inheritance
  - a. Sporadic occurrence in majority of cases
  - b. 19% of cases with more than one affected individuals in the family, providing evidence for a genetic cause
  - c. A genetically (and clinically) heterogeneous disorder
    - i. Autosomal recessive (17.4%)
    - ii. Autosomal dominant (8.7%)
    - iii. X-linked dominant (74%)
2. Chromosomal basis
  - a. Small number of cases with Silver-Russell syndrome reported in association with numerous chromosomal abnormalities
    - i. R(15) and deletion of 15q
    - ii. Diploid–triploid mixoploidy
    - iii. 45,X/46,XY
    - iv. XXY
    - v. Trisomy 18 mosaicism
    - vi. Del(8)(q11-q13)
    - vii. Del(18p)
    - viii. Dup(1)(q32.1-q42.1)
    - ix. Dup(7p12.1-p13)
    - x. Distal chromosome 17q
      - a) Balanced translocation (17;20)(q25;q13) inherited from clinically normal father
      - b) *De novo* translocation (1;17)(q31;q25) with breakpoint recently cloned and localized to 17q23.3-q24
      - c) Heterozygous deletion of the chorionic somatomammotrophin hormone 1 (*CSH1*) gene located within the growth hormone and CSH gene cluster on 17q24.1. The deletion was inherited from the father who appeared clinically normal but had short stature
  - b. Maternal uniparental disomy (UPD) for chromosome 7 (about 7–10% of cases)
    - i. Inheritance of both chromosomes 7 from the mother
    - ii. A possible novel imprinted region at 7p12-p14, 7q32, and 7q31-ter: UPD can disrupt the balance between imprinted genes and thereby lead to phenotypic manifestations
  - iii. Strong evidence of disruption of imprinted gene expression rather than mutation of a recessive


gene underlying the Silver-Russell phenotype in these cases

- c. The majority of the cases, however, have a normal karyotype

### CLINICAL FEATURES

1. Diagnostic criteria: Presence of three major features plus one or more minor features is generally required for a positive diagnosis.
  - a. Major criteria
    - i. Low birth weight (intrauterine growth retardation)
    - ii. Proportionate short stature (postnatal growth retardation): mature height about –3.6 standard deviation scores in both sexes
    - iii. Small triangular face
    - iv. Fifth finger clinodactyly
  - b. Minor criteria
    - i. Relative macrocephaly due to sparing of cranial growth
    - ii. Ear anomalies
    - iii. Skeletal asymmetry (face, limb, or body)
    - iv. Brachydactyly of the fifth fingers
    - v. Bilateral camptodactyly with terminal interphalangeal contractures
    - vi. Syndactyly
    - vii. Transverse palmar crease
    - viii. Downward slanting corner of the mouth
    - ix. Muscular hypotrophy/hypotonia
    - x. Motor/neurological delay
    - xi. Irregular spacing of the teeth
    - xii. Café-au-lait spots
    - xiii. Precocious puberty
    - xiv. Squeaky voice
    - xv. Genital abnormalities
    - xvi. Speech delay
    - xvii. Feeding difficulties
2. Other manifestations
  - a. Significant cognitive impairment (50%)
  - b. Gastrointestinal symptoms (77%)
    - i. Gastroesophageal reflux disease (34%)
    - ii. Esophagitis (25%)
    - iii. Food aversion (32%)
    - iv. Failure to thrive (63%)
  - c. Skeletal anomalies
    - i. Large anterior fontanelle (delayed closure)
    - ii. Absence of asymmetry
    - iii. Syndactyly of the toes
  - d. Genitourinary anomalies
    - i. Hypospadias
    - ii. Posterior urethral valves





In children < 3y.o.

# Growth hormone deficiency

---

- Congenital

Idiopathic GH deficiency, or with:

- other pituitary hormone deficiencies
- with midline defects
- pituitary agenesis, hypoplasia, aplasia and stalk interruption, ectopic anterior pituitary

With gene deficiency GH, GHRH




**Table 1** Human mutations causing abnormal hypothalamo–pituitary development and function.

Gene	Phenotype	Inheritance
Combined pituitary hormone deficiency (CPHD)		
<i>POU1F1</i>	GH, TSH, prolactin deficiencies; usually severe; small or normal AP	Recessive, dominant
<i>PROP1</i>	GH, TSH, LH, FSH, prolactin deficiencies; evolving ACTH deficiency; small, normal or enlarged AP	Recessive
Specific syndrome		
<i>HESX1</i>	IGHD, CPHD, septo-optic dysplasia; APH, EPP, absent infundibulum, ACC	Recessive, dominant
<i>LHX3</i>	CPHD (GH, TSH, LH, FSH, prolactin deficiencies), short neck, limited rotation; small, normal or enlarged AP, short cervical spine	Recessive
<i>LHX4</i>	CPHD (GH, TSH, ACTH deficiencies); small AP, EPP, cerebellar abnormalities	Dominant
<i>SOX3</i>	IGHD and mental retardation, panhypopituitarism; APH, infundibular hypoplasia, EPP	X Linked
<i>SOX2</i>	Hypogonadotropic hypogonadism; APH, bilateral anophthalmia/microphthalmia, abnormal corpus callosum, learning difficulties, oesophageal atresia, sensorineural hearing loss	<i>De novo</i>
<i>TBX19</i>	Neonatal ACTH deficiency	Recessive

AP(H), anterior pituitary (hypoplasia); EPP, ectopic posterior pituitary; ACC, agenesis of corpus callosum.

## Septo-optic dysplasia /HESX1, SOX2 mutation/



**Figure 1** Spectrum of severity of the triad of abnormalities found in septo-optic dysplasia and the variably associated clinical features.

EA Webb and MT Dattani *Septo-optic dysplasia*. European Journal of Human Genetics (2010) 18, 393–397



# Onset of pituitary insufficiency Clinical features 1

---

- GH deficiency: in neonates hypoglycemia, children - short stature, in adults - decreased sense of well-being, lower health-related quality of life, decreased muscle mass, increased fat mass
- TSH deficiency: prolonged jaundice, cold intolerance, dry skin, mental dullness, bradycardia, constipation, anemia (like in primary thyroid failure but clinical changes are less severe and goiter is absent)

## Onset of pituitary insufficiency Clinical features 2

---

- ACTH deficiency: hypoglycemia, weakness, nausea, vomiting, anorexia, weight loss, fever, hypotension (like in primary adrenal failure)
- PRL deficiency- symptom of PRL deficiency is failure of postpartum lactation
- Gonadotropin deficiency: micropenis, hypogonadism, oligomenorrhea, amenorrhea in women in men eunuchoid appearance



# GH deficiency

---

Key elements that may indicate GH deficiency are:

- Height more than 2 SD below the mean.
- Neonatal hypoglycemia, micropenis, prolonged jaundice, or traumatic delivery.
- A peak GH concentration after provocative GH testing is less than 10 ng/ml.
- Consanguinity and/or a family member with GH deficiency.
- Midline defects, pituitary hypo- or aplasia.
- Deficiency of other pituitary hormones: TSH, PRL, LH/FSH and/or ACTH deficiency.

# GH deficiency


## Biochemical evaluation of GH deficiency:

---

As growth hormone is secreted in a pulsatile manner, with little serum GH at any given time, **three methods have been used** to assess the adequacy of GH secretion:

1. Stimulation testing: GH provocation utilizing arginine, clonidine, glucagon, L-Dopa, insulin, etc. This practice generally measures pituitary reserve-or GH secretory ability-rather than endogenous secretory status.
2. GH-dependent biochemical markers: IGF1 and IGFBP3: Values below a cut-off less than -2 SD for IGF1 and/or IGFBP3 strongly suggest an abnormality in the GH axis if other causes of low IGF have been excluded. Age and gender appropriate reference ranges for IGF1 and IGFBP3 are mandatory.
3. Blood sampling at frequent intervals designed to quantify physiologic bursts of GH secretion (e.g. 24-hour or overnight GH sampling)





**Cerebral MRI (T1-weighted images).**

**A, Sagittal slice; B, coronal slice; normal morphology of anterior pituitary and pituitary stalk is seen. The hyperintense signal of the posterior pituitary is in the normal location.**

**C, Sagittal slice; D, Coronal slice; a normal anterior pituitary with a thin pituitary stalk is seen. The ectopic posterior pituitary hyperintense signal is located along the stalk (at a proximal level of the pituitary stalk; *arrow*).**

**E, Sagittal slice; F, coronal slice; hypoplastic anterior pituitary with no visible pituitary stalk after gadolinium injection. The ectopic pituitary hyperintense signal is at the median eminence (*arrow*).**

Reprinted with permission [Leger J, et al. J Clin Endocrinol Metab. 2005;90:650-656](#). Copyright ©2005. The Endocrine Society. All rights reserved.

# Treatment

---

- GH deficiency is treated with biosynthetic recombinant DNA-derived GH.



# Hyposomatotropism hypersomatotropic

---

## Increased GH and decreased IGF-1

GH insensitivity can be caused by genetic defects in GHR, Stat5B, IGF1 (regulatory gen IGF1, IGF1 receptor, post-translational pathway), deficient of IGFBP3/IGFALS complex

# Laron dwarfism

## Clinical features:

Acromicria

Obesity

High-pitched voice

Blue sclerae


Discolored crowded teeth

Hypoglycemia

Sexual maturation

Final heights of adults range from 108-136 cm

**Treatment:- administration of recombinant IGF-1**







Turner syndrome


# Height Velocity: Normal vs Turner Syndrome

## Adolescent growth

- General population average = 13 cm
- Turner syndrome average = 6.5 cm

## General population girls


Yearly growth rate



3, 10, 25, 50, 75, 90, 97 percentiles are shown

Reprinted with permission from standard growth chart provided by Castlemead publications.

## Turner syndrome Height velocity



1983;141(2):81-88.

Ranke MB, et al. *Eur J Pediatr*. 1983;141(2):81-88.



# Turner syndrome

---

- **Sex:** Turner syndrome only occurs in females.
- Noonan syndrome, sometimes inappropriately called male Turner syndrome, can occur in males or females. It is an autosomal dominant disorder and is unrelated.
- **Age:** As a chromosomal disorder, Turner syndrome is present at conception or following the first cell division, and it remains throughout life.
- **Gonadotropins**, particularly follicle-stimulating hormone (FSH), may be elevated at birth, although not reliably enough for use in excluding the diagnosis. They are gradually suppressed by about 4 years of age, only to rise to menopausal levels after age 10 years.

# Turner syndrome

---

Approximately 95% of individuals with Turner syndrome have both short stature and signs of ovarian failure on physical examination.

- **Short stature.** Before age 11 years, some girls have height and growth rates that are well within the normal range, but heights are below the 50th percentile.
- **Ovarian failure:** Suspect ovarian failure in girls who have no breast development by age 12 years or who have not started menses by age 14 years. Elevated levels of luteinizing hormone (LH) and FSH confirm ovarian failure.



# Turner syndrome

---

- **Pubic hair:** Pubic hair development is normal.
- **Nevi:** Excessive numbers of nevi- increased risk of keloid formation.
- **Webbed neck:** Lymphedema in utero can cause a broad neck and a low or indistinct hairline.
- **Cubitus valgus** (increased carrying angle): This is a common skeletal anomaly in girls due to abnormal development of the trochlear head. Other anomalies include Madelung deformities and short fourth and fifth metacarpals or metatarsal.

# Turner syndrome

---

- **Shield chest:** The chest appears to be broad with widely spaced nipples. This may be caused in part by a short sternum.
- **Lymphedema:** It may be present at any age and is one finding that can suggest Turner syndrome. Lymphedema is the cause of other anomalies, such as the webbed neck and low posterior hairline.
- **Eye:** Ptosis, strabismus, amblyopia, and cataracts are more common in girls with Turner syndrome. Epicanthal folds can be present. Red-green color blindness is an X-linked condition and would be expected to occur in girls with Turner syndrome as commonly as it does in males.
- **Ears:** otitis media is more common



# Turner syndrome

---

- Gastrointestinal bleeding
- Hip dislocation: Infants have a higher incidence of congenital hip dislocation.
- Scoliosis: This occurs in 10% of adolescent girls with Turner syndrome and may contribute to short stature. Scoliosis screening is essential.
- Hypertension: Blood pressure elevations may be caused by coarctation of the aorta or renal anomalies but often occur even in the absence of such findings.

# Turner syndrome

---

- Thyroid: As many as half of patients have positive antithyroid antibodies, and 10-30% develop hypothyroidism. This is often associated with thyroid enlargement.
- Cutis laxa
- Prenatal signs: Most concepti with a 45 X karyotype spontaneously abort. Most, if not all, of those who survive to birth are suspected to have mosaicism for a normal cell line. Turner syndrome may be diagnosed prenatally by amniocentesis or chorionic villous sampling.



# Turner syndrome

---

- **Diagnosis**

- A karyotype is required for diagnosis. Diagnosis is confirmed by the presence of a 45 X cell line or a cell line with deletion of the short arm of the X chromosome (Xp deletion).
- The buccal smear for Barr bodies is obsolete.

- **Y chromosome**

- Patients with 45, X/46, XY mosaicism may have mixed gonadal dysgenesis and are at a high risk for gonadoblastoma. These patients may require a prophylactic gonadectomy to prevent death from malignancy.
- Patients with ring chromosomes or fragments of chromosomes should be examined for Y chromosomal material for the same reason.

# Turner syndrome

---

- **Gonadotropins**

- Both LH and FSH may be elevated in untreated patients younger than 4 years. Gonadotropins are later suppressed to normal or near-normal levels, only to rise to menopausal levels after 10 years of age.
- Obtain both LH and FSH levels prior to initiating estrogen replacement therapy.

- **Thyroid function tests**

- Because of the high prevalence of hypothyroidism in Turner syndrome, obtain thyroid function tests at diagnosis.
- Thyroid-stimulating hormone (TSH) measurements should be repeated every 1-2 years or if symptomatic because patients may develop hypothyroidism at a later age.

- **Glucose metabolism**



# Growth disorders


## growth retardation *classification 5*

---

- Familial short stature - this is not disorder. The children have normal growth velocities, and their height curve parallels the third percentile (parents with short stature)

*Constitutional slow growth- normal growth velocities. GH secretions are in normal range.*

## *Constitutional slow growth and development*





# Excessive growth

---

- Familial tall stature
- Metabolic
  - homocystinuria
- Syndromes
  - Cerebral gigantism
  - Beckwith-Wiedeman syndrome
  - Marfan syndrome
  - Klinefelter syndrome
  - XYY syndrome

# Excessive growth

---


## Marfan syndrome

- **Causes**

Marfan Syndrome is caused by a defect in the gene that determines the structure of fibrillin, a protein that is an important part of connective tissue. The defective gene can be inherited.



Fig. 1



This person with the Marfan syndrome is tall and thin and has an arm span that exceeds her height.

Normal  
hands

Marfan  
Syndrome


Elongated finger and arm bones

Normal

Normal  
chest

Marfan  
Syndrome

©MMG 2003






# Excessive growth

---

## Sotos syndrome

- Sotos syndrome was first described by Sotos et al. (1964) in five children with overgrowth, acromegalic features, nonprogressive cerebral disorder with mental retardation and characteristic physiognomy.



**Fig 1.** A) Patient 7 at age 6 months with appearance considered typical of Sotos syndrome. Note the prominent fore-head, telecanthus, epicanthic folds, flat nasal bridge, downslanting palpebral fissures and pointed chin. B) Same patient at age 4 years and 6 months. Photos published with written authorization given by the patient's parents.



# Klinefelter Syndrome 47XXY



- Klinefelter Syndrome occurs in 1 in 500 to 1 in 1000 live births. People with this disorder develop as males with subtle characteristics that become apparent during puberty. They are often tall and usually do not develop secondary sex characteristics such as facial hair, or underarm and pubic hair.
- Men and boys with Klinefelter Syndrome have a Y chromosome and 2 X chromosomes. This is an example of trisomy.

# Excessive growth

---

## Hormonal

- Excess growth hormone /GH- producing tumor/
- Precocious puberty
- CAH – congenital adrenal hyperplasia
- Gonadal tumor
- McCune-Albright syndrome
- Hypertyroidism
- Hyperinsulinemia





2019